2-ethyl-6-methyl-heptanoic acid | 91008-77-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-ethyl-6-methyl-heptanoic acid
• 英文别名: 2-Methyl-octan-carbonsaeure-(6)；2-Aethyl-6-methyl-heptansaeure；Aethyl-isohexyl-essigsaeure；2-Ethyl-6-methyl-heptansaeure；6-Methyl-2-ethylheptanoic acid；2-ethyl-6-methylheptanoic acid
• CAS: 91008-77-4
• 化学式: C₁₀H₂₀O₂
• 分子量: 172.268
• InChiKey: JNTSJBONAWXXDR-UHFFFAOYSA-N

物化性质

• 沸点：
  119 °C(Press: 4 Torr)
• 密度：
  0.90649 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-Carboxy-7-methyl-2,6-octadien-1-ol 在 platinum(IV) oxide 氢气 作用下， 以 乙酸乙酯 为溶剂， 生成 2-ethyl-6-methyl-heptanoic acid
  参考文献：
  名称：

  Stereoselective Synthesis of Nerol

  摘要：

  中文翻译结果：内罗尔，非环单萜醇，已通过使用不饱和羟基酸VI作为中间体进行了立体选择性合成，其中羧基和羟甲基显然处于顺式关系。

  DOI：

  10.1246/bcsj.37.158

文献信息

• [EN] 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES<br/>[FR] DERIVES D'AZETIDINE 1, 3-DISUBSTITUES A UTILISER EN TANT QU'ANTAGONISTES DU RECEPTEUR CCR3 DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES ET ALLERGIQUES
  申请人：NOVARTIS AG

  公开号：WO2005026113A1

  公开（公告）日：2005-03-24

  Compounds of formula Ia or Ib in free or salt form, wherein Ar, X1, X2, m, R1, Q, Y, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by CCR-3, for example an inflammatory or allergic condition, particularly an inflammatory or obstructive airways disease. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  公式Ia或Ib的化合物，无论是自由形式还是盐形式，其中Ar、X1、X2、m、R1、Q、Y、R2和R3的含义如规范中所示，可用于治疗由CCR-3介导的疾病，例如炎症或过敏症状，特别是炎症或阻塞性气道疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• [EN] AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDRS<br/>[FR] DERIVES AZETIDINECARBOXAMIDE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES A MEDIATION DU RECEPTEUR DU CB1
  申请人：VERNALIS RES LTD

  公开号：WO2004096794A1

  公开（公告）日：2004-11-11

  Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors, such as obesity, wherein: R1 is aryl or heteroaryl; R2 is alkyl, aryl or heteroaryl; R3 is alkyl, aryl, heteroaryl, NR9R10, OR 15, or NR 16C(O)R17; Y is C=O, C=S, SO2, or (CR7R8)p; m = 1 or 2; n = 1 or 2; and p=1,2,3 or 4, R7 to R17 being as defined in the specification; wherein if -Y-R3 is -C(O)NH(alkyl) then: R1 and/or R2 is selected from heteroary1; and/or m and/or n is 2; and/or R11 and/or R12 is lower alkyl, or a pharmaceutically acceptable salt or prodrug thereof.

  化合物的化学式（I）及其在治疗中的应用，特别是用于治疗由CB1受体介导的疾病，如肥胖，其中：R1为芳基或杂环芳基；R2为烷基，芳基或杂环芳基；R3为烷基，芳基，杂环芳基，NR9R10，OR 15，或NR 16C(O)R17；Y为C=O，C=S，SO2，或（CR7R8）p；m = 1或2；n = 1或2；p=1,2,3或4，R7到R17如规范中定义；其中如果-Y-R3为-C(O)NH(烷基)则：R1和/或R2从杂芳基中选择；和/或m和/或n为2；和/或R11和/或R12为较低烷基，或其药用盐或前药。
• Azabicyclic ether derivatives and their use as therapeutic agents
  申请人：——

  公开号：US20020193402A1

  公开（公告）日：2002-12-19

  The present invention relates compounds of the formula (I): 1 wherein X represents hydrogen, C 1-4 alkyl optionally substituted by a hydroxy, methoxy or benzyloxy group, or CO 2 (C 1-2 alkyl); Z is —CR 9 R 10 CH 2 — or —CH 2 CR 9 R 10 —; and R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migaine, emesis or postherpetic neuralgia.

  该发明涉及以下式（I）的化合物： 1 其中 X代表氢，C 1-4 烷基，可选择地被羟基，甲氧基或苄氧基取代，或CO 2 （C 1-2 烷基）; Z为—CR 9 R 10 CH 2 —或—CH 2 CR 9 R 10 —; 而R 1 ，R 2 ，R 3 ，R 4 ，R 5 和R 6 如本文所定义。 这些化合物在治疗或预防抑郁症、焦虑、疼痛、炎症、偏头痛、呕吐或带状疱疹后神经痛方面特别有用。
• [EN] 8-AZABICYCLO[3.2.1]OCTANE ETHER DERIVATIVES AND THEIR USE AS NEUROKININ RECEPTOR ANTAGONISTS<br/>[FR] DERIVES D'ETHER 8-AZABICYCLO[3.2.1]OCTANE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DE RECEPTEUR DE NEUROKININE
  申请人：MERCK SHARP & DOHME

  公开号：WO2004031185A1

  公开（公告）日：2004-04-15

  The present invention relates compounds of the formula (I) : wherein X represents hydrogen, C1-4alkyl optionally substituted by a hydroxy, methoxy or benzyloxy group, or CO2(C1-2alkyl); Z is -CR9R10CH2- or -CH2CR9R10-; and R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migaine, emesis or postherpetic neuralgia.

  本发明涉及以下式(I)的化合物：其中X代表氢，C1-4烷基，可选择地被羟基，甲氧基或苄氧基取代，或CO2(C1-2烷基)；Z为-CR9R10CH2-或-CH2CR9R10-；而R1、R2、R3、R4、R5和R6如本文所定义。这些化合物在治疗或预防抑郁症、焦虑、疼痛、炎症、偏头痛、呕吐或带状疱疹后神经痛方面具有特殊用途。
• Crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound
  申请人：——

  公开号：US20030181469A1

  公开（公告）日：2003-09-25

  The invention provides new forms of a chemical compound of formula (I). The invention relates to forms fo a chemical compound (I), in particular to crystalline and amorphous forms, more particularly four crystalline forms and an amorphous form. The invention further relates to processes for the preparation of such forms, to pharmaceutical compositions comprising the compound in crystalline and/or amorphous form and to therapeutic use of such forms. 1

  该发明提供了化学式（I）的化合物的新形式。该发明涉及化学式（I）的形式，特别是晶体和非晶形式，更具体地说是四种晶体形式和一种非晶形式。该发明还涉及制备这些形式的过程，包括该化合物的晶体和/或非晶形式的药物组合物以及这些形式的治疗用途。1